Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of Imatinib Mesylate in Hypereosinophilic Syndromes

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* patients with a diagnosis of HES, CEL and CIH, who are either previously untreated or have been treated with corticosteroids, cytotoxic drugs, and IFN.~* age \> 15 years.~* signature of a written informed consent(by parents/tutors for patients aged \< 18 years).~Exclusion Criteria:~* patients with a diagnosis of secondary hypereosinophilia~* age \< 15 years

- Gender: ALL
- Minimum Age: 15 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Imatinib (Type: EXPERIMENTAL): Patients received oral imatinib 100 mg/d; in case of unsatisfactory response (less than complete) Imatinib could be increased by 100 mg/die on a weekly basis and up to a maximum of 400 mg/die. Imatinib was discontinued after 12 total weeks of therapy.

Based on this trial design, predict the completion outcome and termination type (if applicable).